OxSonics Limited, The Magdalen Centre, Robert Robinson Avenue, Oxford OX4 4GA, United Kingdom.
OxSonics Limited, The Magdalen Centre, Robert Robinson Avenue, Oxford OX4 4GA, United Kingdom.
Ultrasound Med Biol. 2022 Aug;48(8):1681-1690. doi: 10.1016/j.ultrasmedbio.2022.03.010. Epub 2022 May 13.
Ultrasound-induced cavitation is currently under investigation for several potential applications in cancer treatment. Among these, the use of low-intensity ultrasound, coupled with the systemic administration of various cavitation nuclei, has been found to enhance the delivery of co-administered therapeutics into solid tumors. Effective pharmacological treatment of solid tumors is often hampered, among various factors, by the limited diffusion of drugs from the bloodstream into the neoplastic mass and through it, and SonoTran holds the potential to tackle this clinical limitation by increasing the amount of drug and its distribution within the ultrasound-targeted tumor tissue. Here we use a clinically ready system (SonoTran Platform) composed of a dedicated ultrasound device (SonoTran System) capable of instigating, detecting and displaying cavitation events in real time by passive acoustic mapping and associated cavitation nuclei (SonoTran Particles), to instigate cavitation in target tissues and illustrate its performance and safety in a large-animal model. This study found that cavitation can be safely triggered and mapped at different tissue depths and in different organs. No adverse effects were associated with infusion of SonoTran Particles, and ultrasound-induced cavitation caused no tissue damage in clinically targetable organs (e.g., liver) for up to 1 h. These data provide evidence of cavitation initiation and monitoring performance of the SonoTran System and the safety of controlled cavitation in a large-animal model using a clinic-ready platform technology.
超声空化目前正被广泛研究，以期在癌症治疗中得到多种潜在应用。在这些应用中，低强度超声与各种空化核的系统给药相结合，已被发现可增强联合给予的治疗剂向实体瘤的递呈。在多种因素的影响下，实体瘤的有效药物治疗常常受到阻碍，其中包括药物从血液扩散到肿瘤组织中的量有限，以及药物穿过肿瘤组织的量有限。SonoTran 有潜力通过增加药物的数量及其在超声靶向肿瘤组织中的分布来解决这一临床限制。在此，我们使用了一种临床就绪系统（SonoTran 平台），该系统由一个专用的超声设备（SonoTran 系统）组成，该系统能够通过被动声学映射和相关的空化核（SonoTran 粒子）实时引发、检测和显示空化事件，从而在目标组织中引发空化，并在大动物模型中说明其性能和安全性。本研究发现，空化可以在不同的组织深度和不同的器官中安全地触发和定位。SonoTran 粒子的输注没有任何不良反应，并且在长达 1 小时的时间内，超声诱导的空化不会对可临床靶向的器官（如肝脏）造成组织损伤。这些数据为 SonoTran 系统的空化引发和监测性能以及使用临床就绪平台技术的大动物模型中受控空化的安全性提供了证据。
